Abstract
We analyzed 1196 proteins in longitudinal plasma samples from participants in a commercial wellness program, including samples collected pre-diagnosis from ten cancer patients and 69 controls. For three individuals ultimately diagnosed with metastatic breast, lung, or pancreatic cancer, CEACAM5 was a persistent longitudinal outlier as early as 26.5 months pre-diagnosis. CALCA, a biomarker for medullary thyroid cancer, was hypersecreted in metastatic pancreatic cancer at least 16.5 months pre-diagnosis. ERBB2 levels spiked in metastatic breast cancer between 10.0 and 4.0 months pre-diagnosis. Our results support the value of deep phenotyping seemingly healthy individuals in prospectively inferring disease transitions.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Biomarkers, Tumor / blood*
-
Breast Neoplasms / blood
-
Breast Neoplasms / diagnosis
-
Carcinoembryonic Antigen / blood
-
Carcinoma, Neuroendocrine / blood
-
Carcinoma, Neuroendocrine / diagnosis
-
Case-Control Studies
-
GPI-Linked Proteins / blood
-
Health Promotion / statistics & numerical data
-
Humans
-
Longitudinal Studies
-
Lung Neoplasms / blood
-
Lung Neoplasms / diagnosis
-
Male
-
Middle Aged
-
Neoplasm Proteins / blood
-
Neoplasms / blood*
-
Neoplasms / diagnosis
-
Pancreatic Neoplasms / blood
-
Pancreatic Neoplasms / diagnosis
-
Prospective Studies
-
Thyroid Neoplasms / blood
-
Thyroid Neoplasms / diagnosis
-
Time Factors
Substances
-
Biomarkers, Tumor
-
CEACAM5 protein, human
-
Carcinoembryonic Antigen
-
GPI-Linked Proteins
-
Neoplasm Proteins
Supplementary concepts
-
Thyroid cancer, medullary